汪力慧, 李凯. 血管内皮抑素对小鼠体内Lewis肺癌血管生成及转移影响的研究[J]. 中国肿瘤临床, 2008, 35(10): 587-590,698.
引用本文: 汪力慧, 李凯. 血管内皮抑素对小鼠体内Lewis肺癌血管生成及转移影响的研究[J]. 中国肿瘤临床, 2008, 35(10): 587-590,698.
WANG Lihui, LI Kai. The Anti-angiogenic and Anti-metastatic Effect of Endostatin on Lewis Lung Car-cinoma Xenograft in Mice[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 35(10): 587-590,698.
Citation: WANG Lihui, LI Kai. The Anti-angiogenic and Anti-metastatic Effect of Endostatin on Lewis Lung Car-cinoma Xenograft in Mice[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 35(10): 587-590,698.

血管内皮抑素对小鼠体内Lewis肺癌血管生成及转移影响的研究

The Anti-angiogenic and Anti-metastatic Effect of Endostatin on Lewis Lung Car-cinoma Xenograft in Mice

  • 摘要: 目的: 观察血管内皮抑素(Endostatin)对C57小鼠体内Lewis肺癌生长、血管生成及转移的影响。 方法: 将荷Lewis肺癌的C57鼠进行不同剂量组的内皮抑素和顺铂干预,观察肿瘤生长、移植瘤及转移瘤体内的血管内皮生长因子(VEGF)和微血管密度(MVD)的表达及转移发生率,并作统计学分析。 结果: 内皮抑素对鼠Lewis肺癌的生长有明显的抑制作用。内皮抑素处理组(内含400μg、300μg、200μg和200μg+DDP组)和模型组转移率间的差异有统计学意义(P=0.0303)。内皮抑素能显著下调移植瘤及转移瘤内的VEGF。移植瘤中模型组与其余各组之间均存在显著差异(P<0.01);400μg组与200μg组、DDP组、联合用药组之间均存在统计学差异(P<0.05);300μg组与200组之间存在统计学差异(P<0.05);转移瘤中模型组与其余各组之间均存在统计学差异(P<0.05)。300μg与200μg之间有统计学差异(P<0.05),200μg与DDP组和200μg+DDP组之间有统计学差异(P<0.05)。原位移植瘤与肺转移肿瘤组织中VEGF表达呈正相关(r=0.977,P=0.001)。内皮抑素能显著下调移植瘤及转移瘤内和MVD。在移植瘤中400μg和300μg组肿瘤微血管密度最小,彼此无差异;200μg加DDP组肿瘤微血管密度次之,200μg组肿瘤微血管密度再次,DDP组肿瘤微血管密度在各实验组中最多,模型组肿瘤微血管密度最大。在转移瘤中400μg、300μg和200μg组微血管密度最小,这三组彼此无差异。200μg加DDP组肺转移瘤组织微血管密度次之,DDP组肺转移瘤组织微血管密度在各实验组中最多;模型组肿瘤微血管密度最大。内皮抑素可以减少肿瘤肺转移,作用程度在一定范围内与内皮抑素剂量呈正相关。 结论: 血管内皮抑素可以通过下调瘤组织中的VEGF和MVD抑制肿瘤生长及转移。

     

    Abstract: Objective: To investigate the anti-tumor, anti-angiogenic and anti-metastatic effect of endostatin on Lewis lung carcino-ma xenograft in mice. Methods: Different dosages of Endostatin and Cisplatin were given to C57 mice with Lewis lung carcinoma xenograft.Tumor growth, VEGF expression, MVD in planted xenogrft tumor and metastatic tumor, and the metastatic rate were then observed and analyzed. Results: Endostatin obviously inhibited Leweis tumor growth.A signifi-cant difference was found in tumor growth between the group treated with Endostatin and the control group (P=0.0303).Endostatin remarkably down-regulated VEGF expression both in xenograft and metastastic tumor tissues.A positive cor-relation was found between VEGF expression in the xenograft and that in lung metastastic tumor tissues (r=0.977, P= 0.001).Endostatin decreased MVD both in xenograft and metastastic tumor tissues.Tumors treated with Endostatin had less lung metastases, the extent of which depended on the dosage. Conclusion: Endostatin can inhibit the growth and metastases of Lewis lung carcinoma through down-regulating VEGF expression and MVD both in the xenograft and metastatic tumors.

     

/

返回文章
返回